First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
J Greenhalgh, A Boland, V Bates… - Cochrane Database …, 2021 - cochranelibrary.com
Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non‐small cell
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …
[HTML][HTML] Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non–small cell lung cancer
E Castellanos, E Feld, L Horn - Journal of thoracic oncology, 2017 - Elsevier
EGFR-mutated NSCLC is a genetically heterogeneous disease that includes more than 200
distinct mutations. The implications of mutational subtype for both prognostic and predictive …
distinct mutations. The implications of mutational subtype for both prognostic and predictive …
[HTML][HTML] Nivolumab monotherapy for first-line treatment of advanced non–small-cell lung cancer
S Gettinger, NA Rizvi, LQ Chow… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Purpose Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody,
has demonstrated improved survival over docetaxel in previously treated advanced non …
has demonstrated improved survival over docetaxel in previously treated advanced non …
[HTML][HTML] Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang… - Annals of …, 2015 - Elsevier
Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised …
K Park, EH Tan, K O'Byrne, L Zhang, M Boyer… - The Lancet …, 2016 - thelancet.com
Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …
Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: a meta‐analysis
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
[HTML][HTML] Emerging therapies for non-small cell lung cancer
Recent advances in the field of novel anticancer agents prolong patients' survival and show
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …
[HTML][HTML] A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed …
Background While osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small …
tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small …
[HTML][HTML] Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: a clash of the generations
R Shah, JF Lester - Clinical lung cancer, 2020 - Elsevier
The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
Worldwide Frequency of Commonly Detected EGFR Mutations
RP Graham, AL Treece, NI Lindeman… - … of pathology & …, 2018 - meridian.allenpress.com
Context.—Recurrent epidermal growth factor receptor (EGFR) mutations are seen in a
subset of pulmonary adenocarcinomas. These mutations are targeted by EGFR inhibitors …
subset of pulmonary adenocarcinomas. These mutations are targeted by EGFR inhibitors …